Mothers against decapentaplegic homolog 3

SMAD3
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases SMAD3, HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3, SMAD family member 3
External IDs OMIM: 603109 MGI: 1201674 HomoloGene: 55937 GeneCards: SMAD3
Genetically Related Diseases
inflammatory bowel disease, Crohn's disease, asthma, coronary artery disease[1]
RNA expression pattern




More reference expression data
Orthologs
Species Human Mouse
Entrez

4088

17127

Ensembl

ENSG00000166949

ENSMUSG00000032402

UniProt

P84022

Q8BUN5

RefSeq (mRNA)

NM_001145102
NM_001145103
NM_001145104
NM_005902

NM_016769

RefSeq (protein)

NP_001138574.1
NP_001138575.1
NP_001138576.1
NP_005893.1

NP_058049.3

Location (UCSC) Chr 15: 67.06 – 67.2 Mb Chr 9: 63.65 – 63.76 Mb
PubMed search [2] [3]
Wikidata
View/Edit HumanView/Edit Mouse

Mothers against decapentaplegic homolog 3 also known as SMAD family member 3 or SMAD3 is a protein that in humans is encoded by the SMAD3 gene.[4][5] SMAD3 is a member of the SMAD family of proteins. It mediates the signals from the transforming growth factor beta (TGF-β) superfamily ligands that regulate cell proliferation, differentiation and death.[6] Based on its essential role in TGF beta signaling pathway, SMAD3 has been related with tumor growth in cancer development.

Gene

The human SMAD3 gene is located on chromosome 15 with location of the cytogenic band at 15q22.33 is composed of 9 exons over 129,339 base pairs.[7] It is one of several human homologues of a gene that was originally discovered in the fruit fly Drosophila melanogaster.

The expression of SMAD3 has been related to the mitogen-activated protein kinase (MAPK/ERK pathway), particularly to the activity of mitogen-activated protein kinase kinase-1 (MEK1).[8] Studies have demonstrated that inhibition of MEK1 activity inhibits SMAD3 expression in epithelial cells and smooth muscle cells, two cell types highly responsive to TGF-β1.[8]

Structure

SMAD3 is a polypeptide with a molecular weight of 48,080 daltons. It belongs to the SMAD family of proteins, which are essential intracellular signaling components of the TGF-β superfamily. SMAD3 is a receptor-regulated SMAD protein (R-SMAD) that modulates signals of activin and TGF-β isoforms.[7]

SMAD3 is recruited by SARA (SMAD Anchor for Receptor Activation) located in the cytosolic part of the TGF beta receptors and Activin receptors. Once the receptor is activated, SMAD3 is phosphorylated, it dissociates from SARA and forms a heterodimeric complex with SMAD4. Binding of this protein with SMAD4 enables its transmigration into the nucleus where it acts as a transcriptional modulator. SMAD3/SMAD4 complex binds directly but with low affinity to SMAD-binding elements (SBEs), which have the minimal sequence motif CAGAC.[6] SMAD3/SMAD4 complex also binds to the TPA-responsive gene promoter elements, which have the sequence motif TGAGTCAG.[9]

Functions and interactions

TGF-β/SMAD signaling pathway

SMAD3 functions as a transcriptional modulator, binding the TRE (TPA responsive element) in the promoter region of many genes that are regulated by TGF-β. SMAD3 and SMAD4 can also form a complex with c-Fos and c-jun at the AP-1/SMAD site to regulate TGF-β-inducible transcription.[9] The genes regulated by SMAD3-mediated TGFβ signaling affect differentiation, growth and death. TGF-β/SMAD signaling pathway has been shown to have a critical role in the expression of genes controlling differentiation of embryonic stem cells.[10] Some of the developmental genes regulated by this pathway include FGF1, NGF, and WNT11 as well as stem/progenitor cell associated genes CD34 and CXCR4.[11] The activity of this pathway as a regulator of pluripotent cell states requires the TRIM33-SMAD2/3 chromatin reading complex.[10]

TGF-β/SMAD3-induced repression

Besides the activity of TGF-β in the up-regulation of genes, this signaling molecule also induces the repression of target genes containing the TGF-β inhibitory element (TIE).[12][13] SMAD3 plays also a critical role in TGF-β-induced repression of target genes, specifically it is required for the repression of c-myc.The transcriptional repression of c-myc is dependent on direct SMAD3 binding to a repressive SMAD binding element (RSBE), within TIE of the c-myc promoter. The c-myc TIE is a composite element, composed of an overlapping RSBE and a consensus E2F site, which is capable of binding at least SMAD3, SMAD4, E2F4, and p107.[13]

Clinical significance

Diseases

Increased SMAD3 activity has, however, been implicated in the pathogenesis of scleroderma.

SMAD3 is also a multifaceted regulator in adipose physiology and the pathogenesis of obesity and type 2 diabetes. SMAD3-knockout mice have diminished adiposity,[14] with improved glucose tolerance and insulin sensitivity. Despite their reduced physical activity arising from muscle atrophy,[15] these SMAD3-knockout mice are resistant to high-fat-diet induced obesity. SMAD3-knockout mouse is a legitimate animal model of human aneurysms‐osteoarthritis syndrome(AOS), also named Loeys-Dietz Syndrome (type 3). SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via the activation of iNOS. Macrophage depletion and inhibition of iNOS activity prevent aortic aneurysms related to SMAD3 gene mutation[16]

Role in cancer

The role of SMAD3 in the regulation of genes important for cell fate, such as differentiation, growth and death, implies that an alteration in its activity or repressing of its activity can lead to the formation or development of cancer. Also several studies have proven the bifunctional tumor suppressor/oncogene role of TGF beta signaling pathway in carcinogenesis.[17]

One way in which SMAD3 transcriptional activator function is repressed, is by the activity of EVI-1.[18] EVI-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells. The zinc-finger domain of EVI-1 interacts with SMAD3, thereby suppressing the transcriptional activity of SMAD3. EVI-1 is thought to be able to promote growth and to block differentiation in some cell types by repressing TGF-β signalling and antagonizing the growth-inhibitory effects of TGF-β.[18]

Prostate

The activity of SMAD3 in prostate cancer is related with the regulation of angiogenic molecules expression in tumor vascularization and cell-cycle inhibitor in tumor growth.[19][20] The progressive growth of primary tumors and metastases in prostate cancer depends on an adequate blood supply provided by tumor angiogenesis. Studies analyzing SMAD3 levels of expression in prostate cancer cell lines found that the two androgen-independent and androgen receptor-negative cell lines (PC-3MM2 and DU145) have high expression levels of SMAD3. Analysis of the relation between SMAD3 and the regulation of angiogenic molecules suggest that SMAD3 may be one of key components as a repressor of the critical angiogenesis switch in prostate cancer.[20] The pituitary tumor-transforming gene 1 (PTTG1) has also an impact in SMAD3-mediated TGFβ signaling. PTTG1 has been associated with various cancer cells including prostate cancer cells. Studies showed that the overexpression of PTTG1 induces a decrease in SMAD3 expression, promoting the proliferation of prostate cancer cells via the inhibition of SMAD3.[19]

Colorectal

In mice, mutation of SMAD3 has been linked to colorectal adenocarcinoma,[3] increased systemic inflammation, and accelerated wound healing.[4] Studies have shown that mutations in SMAD3 gene promote colorectal cancer in mice.[21][22][23] The altered activity of SMAD3 was linked to chronic inflammation and somatic mutations that contribute to chronic colitis and the development of colorectal cancer.[23] The results generated on mice helped identify SMAD3 like a possible player in human colorectal cancer. The impact of SMAD3 has also been analyzed in colorectal cancer human cell lines, using single-nucleotide polymorphism (SNP) microarray analysis. The results showed reductions in SMAD3 transcriptional activity and SMAD2-SMAD4 complex formation, underlining the critical roles of these three proteins within the TGF-β signaling pathway and the impact of this pathway in colorectal cancer development.[24]

Breast

TGF-β-induced SMAD3 transcriptional regulation response has been associated with breast cancer bone metastasis by its effects on tumor angiogenesis, and epithelial-mesenchymal transition (EMT). There have been identified diverse molecules that act over the TGF-β/SMAD signaling pathway, affecting primarily the SMAD2/3 complex, which have been associated with the development of breast cancer.[25]

FOXM1 (forkhead box M1) is a molecule that binds with SMAD3 to sustain activation of the SMAD3/SMAD4 complex in the nucleus. The research over FOXM1 suggested that it prevents the E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ (TIF1γ) from binding SMAD3 and monoubiquitinating SMAD4, which stabilized the SMAD3/SMAD4 complex. FOXM1 is a key player in the activity of the SMAD3/SMAD4 complex, promoting SMAD3 modulator transcriptional activity, and also plays an important role in the turnover of the activity of SMAD3/SMAD4 complex. Based on the importance of this molecule, studies have found that FOXM1 is overexpressed in highly aggressive human breast cancer tissues. The results from these studies also found that the FOXM1/SMAD3 interaction was required for TGF-β-induced breast cancer invasion, which was the result of SMAD3/SMAD4-dependent upregulation of the transcription factor SLUG.[26]

MED15 is a mediator molecule that promotes the activity of the TGF-β/SMAD signaling. The deficiency of this molecule attenuates the activity of the TGF-β/SMAD signaling pathway over the genes required for induction of epithelial-mesenchymal transition. The action of MED15 is related with the phosphorylation of SMAD2/3 complex. The knockdown of MED15 reduces the amount of SMAD3 phosphorylated, therefore reducing its activity as transcription modulator. However, in cancer, MED15 is also highly expressed in clinical breast cancer tissues correlated with hyperactive TGF-β signaling, as indicated by SMAD3 phosphorylation. The studies suggest that MED15 increases the metastatic potential of a breast cancer cell line by increasing TGF-β-induced epithelial–mesenchymal transition.[27]

Kidney

Smad3 activation plays a role in the pathogenesis of renal fibrosis,[28] probably by inducing activation of bone marrow-derived fibroblasts [29]

Nomenclature

The SMAD proteins are homologs of both the Drosophila protein "mothers against decapentaplegic" (MAD) and the C. elegans protein SMA. The name is a combination of the two. During Drosophila research, it was found that a mutation in the gene MAD in the mother repressed the gene decapentaplegic in the embryo. The phrase "Mothers against" was inspired by organizations formed by mothers to oppose social problems, such as Mothers Against Drunk Driving (MADD); and based on a tradition of such unusual naming within the gene research community.[30]

A reference assembly of SMAD3 is available.

References

  1. ↑ "Diseases that are genetically associated with SMAD3 view/edit references on wikidata".
  2. ↑ "Human PubMed Reference:".
  3. ↑ "Mouse PubMed Reference:".
  4. ↑ "Entrez Gene: SMAD3 SMAD family member 3".
  5. ↑ Zhang Y, Feng X, We R, Derynck R (September 1996). "Receptor-associated Mad homologues synergize as effectors of the TGF-beta response". Nature. 383 (6596): 168–72. doi:10.1038/383168a0. PMID 8774881.
  6. 1 2 Moustakas A, Souchelnytskyi S, Heldin CH (2001). "Smad regulation in TGF-beta signal transduction". J. Cell. Sci. 114 (Pt 24): 4359–69. PMID 11792802.
  7. 1 2 GeneCards. "SMAD3 Gene".
  8. 1 2 Ross KR, Corey DA, Dunn JM, Kelley TJ (May 2007). "SMAD3 expression is regulated by mitogen-activated protein kinase kinase-1 in epithelial and smooth muscle cells". Cell. Signal. 19 (5): 923–31. doi:10.1016/j.cellsig.2006.11.008. PMID 17197157.
  9. 1 2 Zhang Y, Feng XH, Derynck R (1998). "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription". Nature. 394 (6696): 909–13. doi:10.1038/29814. PMID 9732876.
  10. 1 2 Massagué J, Xi Q (2012). "TGF-β control of stem cell differentiation genes". FEBS Lett. 586 (14): 1953–8. doi:10.1016/j.febslet.2012.03.023. PMC 3466472Freely accessible. PMID 22710171.
  11. ↑ Shi X, DiRenzo D, Guo LW, Franco SR, Wang B, Seedial S, Kent KC (2014). "TGF-β/Smad3 Stimulates Stem Cell/Developmental Gene Expression and Vascular Smooth Muscle Cell De-Differentiation". PLoS ONE. 9 (4): e93995. doi:10.1371/journal.pone.0093995. PMC 3981734Freely accessible. PMID 24718260.
  12. ↑ Matrisian LM, Ganser GL, Kerr LD, Pelton RW, Wood LD (1992). "Negative regulation of gene expression by TGF-beta". Mol. Reprod. Dev. 32 (2): 111–20. doi:10.1002/mrd.1080320206. PMID 1637549.
  13. 1 2 Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF (2004). "Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element". Mol. Cell. Biol. 24 (6): 2546–59. doi:10.1128/mcb.24.6.2546-2559.2004. PMC 355825Freely accessible. PMID 14993291.
  14. ↑ Tan CK, Leuenberger N, Tan MJ, Yan YW, Chen Y, Kambadur R, Wahli W, Tan NS (2011). "Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet". Diabetes. 60 (2): 464–76. doi:10.2337/db10-0801. PMC 3028346Freely accessible. PMID 21270259.
  15. ↑ Ge X, McFarlane C, Vajjala A, Lokireddy S, Ng ZH, Tan CK, Tan NS, Wahli W, Sharma M, Kambadur R (2011). "Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts". Cell Res. 21 (11): 1591–604. doi:10.1038/cr.2011.72. PMC 3364732Freely accessible. PMID 21502976.
  16. ↑ Tan CK, Tan EH, Luo B, Huang CL, Loo JS, Choong C, Tan NS (2013). "SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS". J Am Heart Assoc. 2 (3): e000269. doi:10.1161/JAHA.113.000269. PMC 3698794Freely accessible. PMID 23782924.
  17. ↑ de Caestecker MP, Piek E, Roberts AB (2000). "Role of transforming growth factor-beta signaling in cancer". J. Natl. Cancer Inst. 92 (17): 1388–402. doi:10.1093/jnci/92.17.1388. PMID 10974075.
  18. 1 2 Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H (1998). "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3". Nature. 394 (6688): 92–6. doi:10.1038/27945. PMID 9665135.
  19. 1 2 Huang S, Liao Q, Li L, Xin D (2014). "PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation". Tumour Biol. 35 (7): 6265–70. doi:10.1007/s13277-014-1818-z. PMID 24627133.
  20. 1 2 Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z (2007). "Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice". Clin. Cancer Res. 13 (19): 5692–702. doi:10.1158/1078-0432.CCR-07-1078. PMID 17908958.
  21. ↑ Hachimine D, Uchida K, Asada M, Nishio A, Kawamata S, Sekimoto G, Murata M, Yamagata H, Yoshida K, Mori S, Tahashi Y, Matsuzaki K, Okazaki K (2008). "Involvement of Smad3 phosphoisoform-mediated signaling in the development of colonic cancer in IL-10-deficient mice". Int. J. Oncol. 32 (6): 1221–6. doi:10.3892/ijo.32.6.1221. PMID 18497983.
  22. ↑ Seamons A, Treuting PM, Brabb T, Maggio-Price L (2013). "Characterization of dextran sodium sulfate-induced inflammation and colonic tumorigenesis in Smad3(-/-) mice with dysregulated TGFβ". PLoS ONE. 8 (11): e79182. doi:10.1371/journal.pone.0079182. PMC 3823566Freely accessible. PMID 24244446.
  23. 1 2 Kawamata S, Matsuzaki K, Murata M, Seki T, Matsuoka K, Iwao Y, Hibi T, Okazaki K (2011). "Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis". Inflamm. Bowel Dis. 17 (3): 683–95. doi:10.1002/ibd.21395. PMID 20602465.
  24. ↑ Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM (2013). "SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer". Cancer Res. 73 (2): 725–35. doi:10.1158/0008-5472.CAN-12-2706. PMID 23139211.
  25. ↑ Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, Ten Dijke P (2010). "Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis". Oncogene. 29 (9): 1351–61. doi:10.1038/onc.2009.426. PMID 20010874.
  26. ↑ Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, Feng XH, Sawaya R, Medema RH, Hung MC, Huang S (2014). "Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis". J. Clin. Invest. 124 (2): 564–79. doi:10.1172/JCI71104. PMC 3904622Freely accessible. PMID 24382352.
  27. ↑ Zhao M, Yang X, Fu Y, Wang H, Ning Y, Yan J, Chen YG, Wang G (2013). "Mediator MED15 modulates transforming growth factor beta (TGFβ)/Smad signaling and breast cancer cell metastasis". J Mol Cell Biol. 5 (1): 57–60. doi:10.1093/jmcb/mjs054. PMID 23014762.
  28. ↑ Meng XM, Chung AC, Lan HY (Feb 2013). "Role of the TGF-β/BMP-7/Smad pathways in renal diseases..". Clin Sci (Lond).. 124 (4): 243–54. doi:10.1042/CS20120252. PMID 23126427.
  29. ↑ Chen J, Xia Y, Lin X, Feng XH, Wang Y (May 2014). "Smad3 signaling activates bone marrow-derived fibroblasts in renal fibrosis.". Lab Invest. 94 (5): 545–56. doi:10.1038/labinvest.2014.43. PMID 24614197.
  30. ↑ "Sonic Hedgehog, DICER, and the Problem With Naming Genes", Sep 26, 2014, Michael White. psmag.com

Further reading

This article is issued from Wikipedia - version of the 6/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.